Diagnosis & Disease Information

pulmonary fibrosis

New Data Support the Efficacy of TXR-1002 for IPF Treatment

Aria Pharmaceuticals revealed promising results from the third preclinical study of TRX-1002, an idiopathic pulmonary fibrosis (IPF) treatment candidate, that showed a significant decrease in absolute lung weight, fibrosis score, and collagen and hydroxyproline levels.   The findings, revealed in a press release, were presented at the 6th Annual Antifibrotic Drug Development Summit in Boston, Massachusetts. “People suffering from…

LAL-D experimental therapy

Two Drug Candidates Show Promise as Idiopathic Pulmonary Fibrosis Treatments

Two novel pharmaceuticals, TXR-1002 and TXR-1007, demonstrated positive, significant efficacy in decreasing fibrosis within affected lung tissue in mouse models with bleomycin-induced idiopathic pulmonary fibrosis (IPF), compared to standard treatment using nintedanib. The mice with IPF showed a decreased amount of lung collagen staining, reflecting less scar tissue build-up. The researchers also investigated the safety…

Next post in IPF News Briefs